A bioinformatics analysis of the clinicopathological and prognostic significance of <i>FAM64A</i> mRNA expression in gynecological cancers
收藏资源简介：
FAM64A is a mitotic regulator which promotes cell metaphase-anaphase transition and is highly expressed in a cell-cycle-dependent manner. In this study, we examined the clinicopathological and prognostic significance of <i>FAM64A</i> mRNA expression in gynecological cancers. We conducted a bioinformatics analysis of <i>FAM64A</i> mRNA expression using Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), xiantao, The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN), and Kaplan-Meier (KM) plotter databases. <i>FAM64A</i> expression was elevated in breast, cervical, endometrial, and ovarian cancers when compared with normal tissue. Expression was positively correlated with white race, low T stages, infiltrating ductal carcinoma, or favourable PAM50 classification in breast cancer patients, and with clinical stage, histological grade and TP53 mutation, and endometrial cancer serous subtype. <i>FAM64A</i> expression was negatively associated with overall and/or recurrence-free survival rates in breast and endometrial cancer patients, while the opposite was observed in cervical and ovarian cancer patients. <i>FAM64A</i> functioned as an independent predictor of overall and disease-specific survival in breast cancer patients. <i>FAM64A</i>-correlated genes were involved in ligand-receptor interactions, and chromosomal, cell cycle, and DNA replication processes in breast, cervical, endometrial and ovarian cancers. Top hub genes primarily included cell cycle-related proteins in breast cancer, mucins and acetylgalactosaminyl transferases in cervical cancer, kinesin family members in endometrial cancer, and synovial sarcoma X and the cancer/testis antigen in ovarian cancer. <i>FAM64A</i> mRNA expression was positively related to Th2 cell infiltration, but negatively associated with neutrophil and Th17 cell infiltration in breast, cervical, endometrial, and ovarian cancers. <i>FAM64A</i> expression may be considered a potential biomarker reflecting carcinogenesis, histogenesis, aggressive behaviour, and prognosis in gynecological cancers.Impact statement<b>What is already known on this subject?</b> FAM64A is located in cell nucleolar and nucleoplasmic regions, and during mitosis it putatively controls metaphase-to-anaphase transition. FAM64A appears to regulate different physiological processes, including apoptosis, tumorigenesis, neural differentiation, stress responses, and the cell cycle.<b>What</b><b>the results of this study add?</b><i>FAM64A</i> expression was up-regulated in breast, cervical, endometrial, and ovarian cancers, and positively correlated with white race, low T stages, infiltrating ductal carcinoma, or favourable PAM50 classification in breast cancer patients, and with clinical stage, histological grade, and TP53 mutation, and a serous subtype in endometrial cancer. <i>FAM64A</i> expression was negatively associated with overall and/or recurrence-free survival rates in breast and endometrial cancer patients, while the opposite was observed in cervical and ovarian cancer patients. <i>FAM64A</i> functioned as an independent predictor of overall and disease-specific survival in breast cancer. <i>FAM64A</i>-correlated genes were involved in ligand-receptor interactions, chromosomal, cell cycle, and DNA replication processes, while <i>FAM64A</i> mRNA expression was positively related to Th2 cell infiltration but negatively correlated with neutrophil and Th17 cell infiltration in four gynecological cancers.<b>What</b><b>the implications of these findings for clinical practice and/or further research?</b> In the future, abnormal <i>FAM64A</i> mRNA expression may serve as a biomarker of carcinogenesis, histogenesis, aggressiveness, and prognosis in gynecological malignancies. <b>What is already known on this subject?</b> FAM64A is located in cell nucleolar and nucleoplasmic regions, and during mitosis it putatively controls metaphase-to-anaphase transition. FAM64A appears to regulate different physiological processes, including apoptosis, tumorigenesis, neural differentiation, stress responses, and the cell cycle. <b>What</b><b>the results of this study add?</b><i>FAM64A</i> expression was up-regulated in breast, cervical, endometrial, and ovarian cancers, and positively correlated with white race, low T stages, infiltrating ductal carcinoma, or favourable PAM50 classification in breast cancer patients, and with clinical stage, histological grade, and TP53 mutation, and a serous subtype in endometrial cancer. <i>FAM64A</i> expression was negatively associated with overall and/or recurrence-free survival rates in breast and endometrial cancer patients, while the opposite was observed in cervical and ovarian cancer patients. <i>FAM64A</i> functioned as an independent predictor of overall and disease-specific survival in breast cancer. <i>FAM64A</i>-correlated genes were involved in ligand-receptor interactions, chromosomal, cell cycle, and DNA replication processes, while <i>FAM64A</i> mRNA expression was positively related to Th2 cell infiltration but negatively correlated with neutrophil and Th17 cell infiltration in four gynecological cancers. <b>What</b><b>the implications of these findings for clinical practice and/or further research?</b> In the future, abnormal <i>FAM64A</i> mRNA expression may serve as a biomarker of carcinogenesis, histogenesis, aggressiveness, and prognosis in gynecological malignancies.
FAM64A是一种有丝分裂调节因子，可促进细胞中期-后期转换，并以细胞周期依赖性方式高表达。本研究探讨了<i>FAM64A</i> mRNA表达在妇科癌症中的临床病理及预后意义。我们利用Gene Expression Omnibus（GEO，基因表达综合数据库）、The Cancer Genome Atlas（TCGA，癌症基因组图谱）、Xiantao、The University of ALabama at Birmingham CANcer data analysis Portal（UALCAN，阿拉巴马大学伯明翰分校癌症数据分析门户）及Kaplan-Meier（KM，凯普兰-迈耶）绘图器数据库，对<i>FAM64A</i> mRNA表达开展了生物信息学分析。与正常组织相比，<i>FAM64A</i>在乳腺癌、宫颈癌、子宫内膜癌及卵巢癌组织中的表达水平显著升高。在乳腺癌患者中，其表达与白人种族、低T分期、浸润性导管癌或良好的PAM50分型呈正相关；在子宫内膜癌患者中，其表达与临床分期、组织学分级、TP53突变及浆液性亚型呈正相关。<i>FAM64A</i>表达与乳腺癌和子宫内膜癌患者的总生存期及/或无复发生存期呈负相关，而在宫颈癌和卵巢癌患者中则观察到相反的关联。<i>FAM64A</i>可作为乳腺癌患者总生存期和疾病特异性生存期的独立预测因子。<i>FAM64A</i>相关基因在乳腺癌、宫颈癌、子宫内膜癌及卵巢癌中参与配体-受体相互作用、染色体、细胞周期及DNA复制过程。核心枢纽基因主要包括：乳腺癌中与细胞周期相关的蛋白，宫颈癌中的黏蛋白及乙酰半乳糖胺基转移酶，子宫内膜癌中的驱动蛋白家族成员，卵巢癌中的滑膜肉瘤X蛋白及癌症-睾丸抗原。<i>FAM64A</i> mRNA表达与四种妇科癌症中的Th2细胞浸润呈正相关，但与中性粒细胞和Th17细胞浸润呈负相关。<i>FAM64A</i>表达或可作为反映妇科癌症发生、组织发生、侵袭行为及预后的潜在生物标志物。<b>Impact statement</b><br><b>What is already known on this subject?</b> FAM64A定位于细胞核仁及核质区域，在有丝分裂过程中推测可调控中期-后期转换。FAM64A似乎可调控多种生理过程，包括细胞凋亡、肿瘤发生、神经分化、应激反应及细胞周期。<br><b>What the results of this study add?</b> <i>FAM64A</i>在乳腺癌、宫颈癌、子宫内膜癌及卵巢癌中表达上调；在乳腺癌患者中，其表达与白人种族、低T分期、浸润性导管癌或良好的PAM50分型呈正相关，在子宫内膜癌患者中则与临床分期、组织学分级、TP53突变及浆液性亚型呈正相关。<i>FAM64A</i>表达与乳腺癌和子宫内膜癌患者的总生存期及/或无复发生存期呈负相关，而在宫颈癌和卵巢癌患者中观察到相反的关联。<i>FAM64A</i>可作为乳腺癌患者总生存期和疾病特异性生存期的独立预测因子。<i>FAM64A</i>相关基因参与配体-受体相互作用、染色体、细胞周期及DNA复制过程；同时，<i>FAM64A</i> mRNA表达与四种妇科癌症中的Th2细胞浸润呈正相关，但与中性粒细胞和Th17细胞浸润呈负相关。<br><b>What the implications of these findings for clinical practice and/or further research?</b> 未来，异常表达的<i>FAM64A</i> mRNA或可作为妇科恶性肿瘤发生、组织发生、侵袭性及预后的生物标志物。<br><b>What is already known on this subject?</b> FAM64A定位于细胞核仁及核质区域，在有丝分裂过程中推测可调控中期-后期转换。FAM64A似乎可调控多种生理过程，包括细胞凋亡、肿瘤发生、神经分化、应激反应及细胞周期。<br><b>What the results of this study add?</b> <i>FAM64A</i>在乳腺癌、宫颈癌、子宫内膜癌及卵巢癌中表达上调；在乳腺癌患者中，其表达与白人种族、低T分期、浸润性导管癌或良好的PAM50分型呈正相关，在子宫内膜癌患者中则与临床分期、组织学分级、TP53突变及浆液性亚型呈正相关。<i>FAM64A</i>表达与乳腺癌和子宫内膜癌患者的总生存期及/或无复发生存期呈负相关，而在宫颈癌和卵巢癌患者中观察到相反的关联。<i>FAM64A</i>可作为乳腺癌患者总生存期和疾病特异性生存期的独立预测因子。<i>FAM64A</i>相关基因参与配体-受体相互作用、染色体、细胞周期及DNA复制过程；同时，<i>FAM64A</i> mRNA表达与四种妇科癌症中的Th2细胞浸润呈正相关，但与中性粒细胞和Th17细胞浸润呈负相关。<br><b>What the implications of these findings for clinical practice and/or further research?</b> 未来，异常表达的<i>FAM64A</i> mRNA或可作为妇科恶性肿瘤发生、组织发生、侵袭性及预后的生物标志物。
